M. Liu

Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL‐1601D with US and European insulin aspart in healthy volunteers: A randomized, double‐blind, crossover, euglycaemic glucose clamp study

U. Hövelmann, Y. Raiter, Anoop Chullikana, 2021, Diabetes, obesity & metabolism.

A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL‐1401O vs. EU‐trastuzumab and US‐trastuzumab

C. Waller, Andrew R Shaw, M. Liu, 2018, British journal of clinical pharmacology.

A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim

C. Waller, Andrew R Shaw, M. Liu, 2018, Journal of Cancer Research and Clinical Oncology.

Comparison of Immunogenicity between the Proposed Pegfilgrastim Biosimilar MYL-1401H and Reference Pegfilgrastim

L. Mattano, C. Waller, M. Liu, 2017 .

A bioequivalence study of proposed bevacizumab biosimilar, MYL-1402O (A) vs EU-Avastin (B) and US-Avastin (C).

M. Socinski, M. Hummel, Andrew R Shaw, 2017 .

A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab

M. Socinski, M. Hummel, C. Waller, 2021, Journal of Cancer Research and Clinical Oncology.

The Comparative Bioavailability of Fluticasone and Azelastine Delivered as a Single Fixed Dose Combination (MP-AzeFlu) in Comparison to Two Different Formulations of Azelastine and Fluticasone Propionate Following Intranasal Administration in Healthy Chinese Volunteers

J. Gorski, M. Liu, W. Xue, 2023, Journal of asthma and allergy.